Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Cash & Equivalents (2016 - 2025)

Collegium Pharmaceutical has reported Cash & Equivalents over the past 10 years, most recently at $231.3 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $231.3 million for Q4 2025, up 227.71% from a year ago — trailing twelve months through Dec 2025 was $231.3 million (up 227.71% YoY), and the annual figure for FY2025 was $231.3 million, up 227.71%.
  • Cash & Equivalents for Q4 2025 was $231.3 million at Collegium Pharmaceutical, up from $150.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for COLL hit a ceiling of $283.7 million in Q2 2023 and a floor of $39.0 million in Q3 2024.
  • Median Cash & Equivalents over the past 5 years was $178.2 million (2021), compared with a mean of $173.0 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 84.93% in 2024 and later skyrocketed 285.26% in 2025.
  • Collegium Pharmaceutical's Cash & Equivalents stood at $186.4 million in 2021, then dropped by 6.83% to $173.7 million in 2022, then soared by 37.57% to $238.9 million in 2023, then plummeted by 70.47% to $70.6 million in 2024, then soared by 227.71% to $231.3 million in 2025.
  • The last three reported values for Cash & Equivalents were $231.3 million (Q4 2025), $150.1 million (Q3 2025), and $117.3 million (Q2 2025) per Business Quant data.